Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders.

Cerecin and IMCB signed a Memorandum of Understanding to collaborate in the areas of neurometabolism, neurodegeneration, metabolic regulators, and brain health and function. SINGAPORE and DENVER, Dec. 1, 2023 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company at the forefront o...